The Innovation and Value Initiative (IVI) appreciates the opportunity to provide comments to the Centers for Medicare and Medicaid Services (CMS) on the revised draft guidance for implementation of the Medicare Drug Price Negotiation Program (DPNP) for initial price applicability year 2027 and manufacturer effectuation of the maximum fair price (MFP) in 2026 and 2027.
Read the full comments here.